Baxter presents data at 58th era-edta congress indicating theranova may reduce cardiovascular events and hospitalizations

Deerfield, ill.--(business wire)-- #hdx--baxter international inc. (nyse:bax), a global innovator in renal care, announced today new data showing expanded hemodialysis (hdx) therapy enabled by the theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of colombian dialysis patients treated with long-term hdx compared to propensity-matched patients treated with high-flux hemodialysis.1 the study “effectiven
BAX Ratings Summary
BAX Quant Ranking